Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a corporate governance event. The report date is December 19, 2014, covering an event that occurred on December 17, 2014.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of a senior executive:
- Laurence E. Reid, Ph.D. resigned as Senior Vice President and Chief Business Officer.
- The resignation is effective December 31, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the executive departure.
Investor Verification Checklist
- Confirm the effective date of Laurence E. Reid's departure (December 31, 2014).
- Verify if a successor has been appointed for the Chief Business Officer role.
- Review subsequent filings for any impact on the company's business development strategy.